Brielle Benyon | Authors

Naratuximab Emtansine/Rituximab Yields Promising Responses in DLBCL

December 13, 2021

Treatment with naratuximab emtansine and rituximab appeared to be well-tolerated with efficacious responses in a population of patients with B-cell non-Hodgkin lymphomas who were ineligible for stem cell transplant or CAR-T cell therapy.